TW200730200A - Method for the preparation of a wet granulated drug product - Google Patents
Method for the preparation of a wet granulated drug productInfo
- Publication number
- TW200730200A TW200730200A TW095122891A TW95122891A TW200730200A TW 200730200 A TW200730200 A TW 200730200A TW 095122891 A TW095122891 A TW 095122891A TW 95122891 A TW95122891 A TW 95122891A TW 200730200 A TW200730200 A TW 200730200A
- Authority
- TW
- Taiwan
- Prior art keywords
- preparation
- drug product
- wet granulated
- granulated drug
- angiotensin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a method for the preparation of a solid dosage form comprising an angiotensin II receptor antagonist and a calcium channel blocker, said method comprising a step of preparing by wet granulation a composition comprising said angiotensin II receptor antagonist and said calcium channel blocker. The solid dosage form obtainable by the method of the present invention demonstrates improved dissolution properties.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005187212 | 2005-06-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200730200A true TW200730200A (en) | 2007-08-16 |
TWI407978B TWI407978B (en) | 2013-09-11 |
Family
ID=37114405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095122891A TWI407978B (en) | 2005-06-27 | 2006-06-26 | Method for the preparation of a wet granulated drug product |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP5063370B2 (en) |
TW (1) | TWI407978B (en) |
WO (1) | WO2007001065A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103127110A (en) * | 2013-03-18 | 2013-06-05 | 吉林省博大伟业制药有限公司 | Compound preparation containing angiotensin II receptor antagonist and calcium channel blocker |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100237530A1 (en) * | 2006-06-27 | 2010-09-23 | Daiichi Sankyo Company, Limited | Compressed preparation |
TWI399223B (en) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | Solid dosage form of olmesartan medoxomil and amlodipine |
TWI488658B (en) * | 2006-12-26 | 2015-06-21 | Daiichi Sankyo Co Ltd | Method for improvement of elution |
TWI414310B (en) * | 2006-12-26 | 2013-11-11 | Daiichi Sankyo Co Ltd | Elution-improved pharmaceutical preparation |
TWI402083B (en) * | 2006-12-26 | 2013-07-21 | Daiichi Sankyo Co Ltd | Solid dosage form and stabilization method thereof |
CN101416966B (en) * | 2007-10-22 | 2010-11-10 | 鲁南制药集团股份有限公司 | Medical composition capable of treating hypertension |
WO2009113420A1 (en) * | 2008-03-13 | 2009-09-17 | 第一三共株式会社 | Improvement of dissolvability of preparation containing olmesartan medoxomil |
JP5296456B2 (en) * | 2008-08-26 | 2013-09-25 | 大日本住友製薬株式会社 | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet |
NZ594738A (en) | 2009-01-23 | 2013-11-29 | Hanmi Science Co Ltd | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
PE20120315A1 (en) * | 2009-04-30 | 2012-04-07 | Takeda Pharmaceutical | A PHARMACEUTICAL COMPOSITION INCLUDING CANDESARTAN, CANDESARTAN CILEXETIL, OR AZILSARTAN, COMBINED WITH AMLODIPINE |
CN101596195B (en) * | 2009-05-15 | 2011-09-28 | 迪沙药业集团有限公司 | Oral medicine composite for reducing blood pressure |
US9173848B2 (en) * | 2009-06-30 | 2015-11-03 | Sanofi | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application |
JP5421945B2 (en) * | 2010-03-10 | 2014-02-19 | 大日本住友製薬株式会社 | Pharmaceutical composition containing irbesartan and amlodipine or a salt thereof |
EP2425859A1 (en) * | 2010-08-08 | 2012-03-07 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Olmesartan formulations |
KR101778050B1 (en) * | 2012-10-12 | 2017-09-13 | 이에이 파마 가부시키가이샤 | Method for producing pharmaceutical preparation containing calcium antagonist/angiotensin ii receptor antagonist |
MX2013001277A (en) * | 2013-01-31 | 2014-07-30 | Miguel Ángel García Pérez | Pharmaceutical composition comprising an angiotensin ii-receptor antagonist and a calcium channel blocker for the treatment of arterial hypertension. |
JP5714652B2 (en) * | 2013-06-13 | 2015-05-07 | 大日本住友製薬株式会社 | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet |
CN104434823A (en) * | 2013-09-17 | 2015-03-25 | 许昌恒生制药有限公司 | Manidipine hydrochloride tablets and preparation method thereof |
EP2883539A1 (en) | 2013-12-12 | 2015-06-17 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of olmesartan and amlodipine |
JP5978335B2 (en) * | 2015-03-11 | 2016-08-24 | 大日本住友製薬株式会社 | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet |
JP6445923B2 (en) * | 2015-04-22 | 2018-12-26 | ダイト株式会社 | Preparation of irbesartan-containing tablets |
CN104997778A (en) * | 2015-07-08 | 2015-10-28 | 南京正大天晴制药有限公司 | Olmesartan medoxomil and amlodipine medicinal composition |
JP2017210435A (en) * | 2016-05-25 | 2017-11-30 | ダイト株式会社 | Method for producing irbesartan and amlodipine besylate-containing tablet |
JP6151413B2 (en) * | 2016-07-25 | 2017-06-21 | 大日本住友製薬株式会社 | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet |
CN106580992A (en) * | 2016-11-10 | 2017-04-26 | 许昌恒生制药有限公司 | Manidipine hydrochloride and irbesartan compound tablet for treating high blood pressure and preparation method |
JP2017141299A (en) * | 2017-05-24 | 2017-08-17 | 大日本住友製薬株式会社 | Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet |
JP2018168185A (en) * | 2018-07-05 | 2018-11-01 | 大日本住友製薬株式会社 | Irbesartan-containing pharmaceutical composition and orally disintegrable tablet with excellent elution |
JP2019203031A (en) * | 2019-09-06 | 2019-11-28 | 大日本住友製薬株式会社 | Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
JP2003034655A (en) * | 2001-05-15 | 2003-02-07 | Takeda Chem Ind Ltd | Fast degradable solid tablet |
JP2003104888A (en) * | 2001-09-28 | 2003-04-09 | Taiyo Yakuhin Kogyo Kk | Tablet of dihydropyridine derivative |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
JP2008528456A (en) * | 2005-01-26 | 2008-07-31 | レツク・フアーマシユーテイカルズ・デー・デー | Novel pharmaceutical composition comprising candesartan cilexetil as lipophilic crystalline substance |
-
2006
- 2006-06-26 JP JP2007558254A patent/JP5063370B2/en active Active
- 2006-06-26 TW TW095122891A patent/TWI407978B/en active
- 2006-06-26 WO PCT/JP2006/313174 patent/WO2007001065A2/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103127110A (en) * | 2013-03-18 | 2013-06-05 | 吉林省博大伟业制药有限公司 | Compound preparation containing angiotensin II receptor antagonist and calcium channel blocker |
Also Published As
Publication number | Publication date |
---|---|
JP5063370B2 (en) | 2012-10-31 |
JP2008543727A (en) | 2008-12-04 |
WO2007001065A3 (en) | 2007-05-03 |
TWI407978B (en) | 2013-09-11 |
WO2007001065A2 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200730200A (en) | Method for the preparation of a wet granulated drug product | |
TW200740459A (en) | Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker | |
WO2007001067A3 (en) | Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker | |
WO2008051942A3 (en) | Farnesoid x receptor agonists | |
TN2009000093A1 (en) | Pharmaceutical compositions comprising nilotinib or its salt | |
MX2009010556A (en) | Modified dosage forms of tacrolimus. | |
WO2006082523A3 (en) | Pharmaceutical sustained release composition of metformin | |
UA99136C2 (en) | Improved pharmaceutical composition comprising a calcium channel antagonist such as lercanidipine, process for the preparation thereof | |
PL2054411T3 (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | |
WO2007050802A3 (en) | Novel opioid antagonists | |
WO2007076260A3 (en) | Farnesoid x receptor agonists | |
WO2007052289A3 (en) | Novel dispersible tablet composition | |
WO2007044796A3 (en) | Pyridazinone compounds as calcilytics | |
WO2010146179A3 (en) | Solid pharmaceutical composition comprising rivaroxaban | |
MX349221B (en) | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same. | |
IL195514A (en) | Substituted pyridyl compounds, pharmaceutical compositions comprising them, uses thereof as modulators of the histamine h3 receptor and method for their preparation | |
MX2009010167A (en) | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent. | |
MY160432A (en) | Antihypertensive pharmaceutical composition | |
WO2009071650A3 (en) | Amide compounds as boosters of antivirals | |
WO2007044251A3 (en) | Pharmaceutical compositions | |
UA95274C2 (en) | Solid pharmaceutical composition comprising irbesartan and processes for the manufacture thereof | |
CL2007003503A1 (en) | COMPOUNDS DERIVED FROM INDOL-2-IL-CARBONIL-PIPERIDINA-BENZOIMIDAZOLONA AND INDOL-2-IL-CARBONIL-PIPERIDINA-BENZOXAZOLONA, ANTAGONISTS OF THE V1A RECEIVER; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE FOR DISMENORREA TREATMENT | |
UA105285C2 (en) | Solid pharmaceutical composition comprising ramipril and amlodipine besilate and method for its preparation | |
WO2007029093A3 (en) | Pharmaceutical dosage forms of oxcarbazepine | |
WO2011087765A3 (en) | Methods of producing stabilized solid pharmaceutical compositions containing morphinans |